Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 70518-2003

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-2003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mm2 (Divalproex Sodium 500mg 70518 2003 01)

Mm2 (Divalproex Sodium 500mg 70518 2003 01)
Divalproex Sodium 500 mg extended-release film-coated tablets in a quantity of 100. The label indicates repackaging by RemedyRepack Inc., with manufacturing by Aurobindo in India. The label includes NDC 70518-2003-01 and storage instructions.*
FDA Label Image

Mm3 (Divalproex Sodium 500mg 70518 2003 02)

Mm3 (Divalproex Sodium 500mg 70518 2003 02)
Divalproex Sodium extended-release tablet, 500 mg strength, quantity of 1 tablet. The label includes a QR code, NDC number 70518-2003-02, and manufacturer information for Aurobindo, India. It is repackaged by RemedyRepack Inc., Indiana, PA, with storage instructions and a note to see the package insert for directions.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Label for Divalproex Sodium extended-release 500 mg tablets, quantity of 30, repackaged by RemedyRepack Inc. The label includes storage instructions, a QR code, and manufacturing details indicating production by Aurobindo in India. The product is marked RX only and includes the NDC 70518-2003-00.*
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A cumulative distribution plot comparing the percentage of patients on the x-axis to the percentage reduction in CPS rate on the y-axis for Divalproex Sodium delayed-release tablets versus placebo. The graph shows improvement and worsening from 0% change, with Divalproex Sodium demonstrating generally greater reduction in CPS rate than placebo.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A cumulative percentage plot showing the percent reduction in CPS rate versus percent of patients for high dose and low dose Divalproex sodium delayed-release tablets. The vertical axis quantifies change from worsening to improvement, and the horizontal axis shows the distribution percentage of patients. Two lines represent the effects of high dose and low dose treatments on CPS rate reduction.*
FDA Label Image

Figure-3 (Divalproex Fig3)

Figure-3 (Divalproex Fig3)
A bar graph comparing two groups: placebo and Divalproex Sodium Extended-Release Tablets. The y-axis measures a variable ranging from 0 to 1.2. The placebo group has a bar height of 0.6, while the Divalproex Sodium group reaches 1.2, indicating a statistically significant difference (p=0.006).*
FDA Label Image

Structure (Divalproex Str)

Structure (Divalproex Str)
Chemical structure diagram of divalproex sodium showing the polymeric structure with sodium ions indicated. The diagram illustrates the molecular composition relevant to the active ingredient divalproex sodium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.